Massimo Lopez

3.0k citations
59 papers · 2.2k indexed · 1 hit paper · h-index 21

Massimo Lopez

59 papers receiving 2.1k citations

Hit Papers

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in t...5862005202620122019100200300400500

Peers

Massimo Lopez
Comparison fields: 5 of 94
  • Oncology 1.6k
  • Hepatology 274
  • Cancer Research 516
  • Pulmonary and Respiratory Medicine 598
  • Dermatology 133
Replace Per‐Ebbe Jönsson with:
Per‐Ebbe Jönsson Sweden
Frank A. Scappaticci United States
S. Kakolyris Greece
D. Depisch Austria
B. Massidda Italy
J. L. Misset France
G. Deplanque France
Nobuyuki Mizunuma Japan
G Brufman Israel
Roger Faroux France
Massimo Lopez relative to Per‐Ebbe Jönsson Sweden Per‐Ebbe Jönsson's profile →
Citations per field
00.5×
Per‐Ebbe Jönsson · 1×
Citations per year

Countries citing papers authored by Massimo Lopez

Since Specialization
Citations

This map shows the geographic impact of Massimo Lopez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Lopez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Lopez more than expected).

Fields of papers citing papers by Massimo Lopez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Massimo Lopez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Lopez. The network helps show where Massimo Lopez may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Massimo Lopez, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Massimo Lopez Line = papers co-authored together Massimo Lopez links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 201118
2 201017
3 20107
4 20107
5 200938
6
Epigenome: a new target in cancer therapy.
200912
7 200811
8 200840
9 200423
10 200017
11 19995
12 199916
13 19988
14 19949
15 19944
16 199325
17 19917
18 199110
19 199113
20 198934

About Massimo Lopez

Massimo Lopez is a scholar working on Oncology, Cancer Research and Dermatology, having authored 59 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (26 papers), Breast Cancer Treatment Studies (13 papers), Colorectal Cancer Treatments and Studies (10 papers), Neutropenia and Cancer Infections (8 papers), HER2/EGFR in Cancer Research (7 papers), Chemotherapy-induced cardiotoxicity and mitigation (7 papers), Gastric Cancer Management and Outcomes (5 papers) and Chemotherapy-related skin toxicity (5 papers). The work is most often cited by research in Oncology (1.6k citations), Hepatology (274 citations) and Cancer Research (516 citations). Massimo Lopez has collaborated with scholars based in Italy, United States and Malaysia. Frequent co-authors include Vittorio Gebbia, Francesco Giuliani, Giuseppe Colucci, Evaristo Maiello, Luigi Di Lauro, S. Cigolari, Maria Biglietto, Antonio Testa, Generoso Uomo and Paola Papaldo. Their work appears in journals such as Oncology, Journal of Clinical Oncology, Cancer, Investigational New Drugs and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026